Germany's medicine regulator will allow patients with treatment-resistant depression to try psilocybin therapy, marking a significant shift towards mainstream medicine for psychedelics. This is the first instance in the EU where psilocybin will be available through a compassionate use scheme for serious illnesses. The Central Institute of Mental Health (CIMH) emphasizes the importance of controlled conditions and medical supervision for psilocybin therapy. While studies suggest psilocybin may help those unresponsive to standard treatments, skepticism remains about replicability of psychedelic drug studies. Interest in psychedelic therapies is growing, with other countries like the Czech Republic also legalizing psilocybin for medical use. Teljes cikk (Euronews.com)